Adults Archives - Page 3 of 7

Home
/
Projects
/

Adults

Prevention is better than cure’: a mixed methods study of communities’ and healthcare workers’ perspectives on new adult and adolescent TB vaccines and their implementation in Zambia

2024

Mixed methods study examining community members' and healthcare workers' views on future TB vaccines for adults and adolescents in Zamibia. It assesses willingness to receive a TB vaccine, preferred vaccine characteristics, concerns about safety and efficacy, trusted information sources, barriers to uptake, and preferred approaches for vaccine delivery and implementation.

TB vaccine advocacy and acceptance in South Africa

2024

Gathering a range of perspectives to provide early-stage insights into TB vaccine advocacy and acceptance in South Africa

Prep4TBVax

2023-2025

M72/AS01e, MTBVAC

New TB vaccines are likely to be crucial in addressing the ongoing TB pandemic. With multiple promising vaccine candidates in the pipeline and the earliest availability of a candidate expected by 2028, it is of outmost importance that once available, the vaccine can be implemented rapidly and effectively. Limited research has looked at the delivery strategies available to provide a new TB vaccine to beneficiaries and therefore, this study assesses the acceptability and feasibility of delivery strategies for the vaccine candidates M72/AS01e and MTBVAC in Ethiopia, Nigeria, and Tajikistan.

Potential implications of reduced tuberculosis vaccine efficacy in those with undernutrition on overall vaccine impact in India

Hypothetical vaccines

Nutritional status is a leading risk factor for tuberculosis (TB). In India up to half of all TB episodes are attributed to undernutrition. Given the impact of nutrition on the immune system, vaccine characteristics such as efficacy and duration of protection could vary depending on nutritional status. Therefore, previous vaccine impact estimates may be overestimated. We re estimated vaccine impact in India with reduced efficacy with undernutrition

The implications of using different time horizons when evaluating investment to prevent infectious disease

Hypothetical vaccines

A lifetime time horizon is conventional for cost-effectiveness analysis, but not routine for transmission-dynamic modeling, given uncertainty in future epidemiological dynamics and high computation costs. We demonstrate implications of alternative analytic time horizons with a case study of novel tuberculosis (TB) vaccine introduction

Impact of targeted tuberculosis vaccination among a mining population in South Africa: A model based study

2017

Hypothetical vaccines

We developed an individual-based TB transmission model representing a hypothetical population consisting of people who worked in South African gold mines or lived in associated labor-sending communities. We simulated the implementation of a postinfection adult vaccine with 60% efficacy and a mean effect duration of 10 years.

Potential impact of tuberculosis vaccines in China, South Africa, and India

2020

BCG revaccination, M72/AS01e

To inform vaccine development decision making, we modeled the impact of hypothetical tuberculosis vaccines in three high-burden countries.

The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug resistant tuberculosis in India and China

2021

Hypothetical vaccines

We investigated the epidemiologic impact, cost-effectiveness, and budget impact of hypothetical novel prophylactic prevention of disease TB vaccines on RR/MDR-TB in China and India.

Potential impact of spatially targeted adult tuberculosis vaccine in Gujarat, India

2016

Hypothetical vaccines

we aimed to estimate the impact of vaccine delivery strategies that were targeted to high-incidence geographical 'hotspots' compared with randomly allocated vaccination. We developed a spatially explicit mathematical model of TB transmission that distinguished these hotspots from the general population.

The health and economic benefits possible with novel tuberculosis vaccines – A modeling study in India and Indonesia

2021

M72/AS01e

We estimated gains possible with novel post-exposure vaccines, in India and Indonesia. We modeled vaccine impact on TB incidence, TB mortality, and on national income growth and the intrinsic value of living longer, known as Full-income.